FDA chief frames biosimilar insulin as answer to 'intolerable' prices 15-May-2019 By Nick Taylor Acting US FDA commissioner thinks incoming changes to the regulation of insulin may counter the ‘whopping’ price increases seen in recent years.
‘Not business as usual at FDA’: Only addressing immediate threats due to shutdown 15-Jan-2019 By Maggie Lynch The US FDA is faced with lapsed funding appropriations as the US government shutdown continues, causing the agency to focus on addressing immediate threats to consumer safety.
